特发性肺纤维化相关靶向药物研究进展

Research progress of targeted drugs for idiopathic pulmonary fibrosis

吡非尼酮和尼达尼布用于临床显示有效以后,针对特发性肺纤维化的药物治疗便开始以抗纤维化为主。目前关于特发性肺纤维化的研究主要针对发病机制和治疗靶点,越来越多的靶向药物逐步进入临床试验。该文通过检索文献,总结了近期吡非尼酮和尼达尼布单独或联合用药治疗特发性肺纤维化的研究结果,并对现在正进行各期临床研究的基于分子生物学的新靶点抗纤维化药物的机制和试验结果作一综述,旨在为如何选择药物治疗特发性肺纤维化提供依据。

After pirfenidone and nintedanib showed efficacy,drug treatment for idiopathic pulmonary fibrosis began to focused on anti-fibrosis.Current research on idiopathic pulmonary fibrosis mainly focus on the pathogenesis and therapeutic targets,and more targeted drugs are gradually entering clinical trials.This article summarizes the results of recent studies on the treatment of idiopathic pulmonary fibrosis with pirfenidone and nintedanib alone or in combination by searching the literature,and reviews the mechanism and test results of the new target anti-fibrosis drugs based on molecular biology that are currently undergoing clinical research in various phases,and aims to provide a basis for how to choose drugs to treat idiopathic pulmonary fibrosis.